A double-blind, placebo-controlled study of memantine in the treatment of major depression.

Glutamate receptor ion channels: structure, regulation, and function. Pharmacol Rev (2010) 11.25

NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci (2013) 4.35

Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic deficits caused by chronic stress exposure. Biol Psychiatry (2011) 3.62

Allosteric modulators of NR2B-containing NMDA receptors: molecular mechanisms and therapeutic potential. Br J Pharmacol (2009) 1.94

Rapid-acting glutamatergic antidepressants: the path to ketamine and beyond. Biol Psychiatry (2013) 1.92

GLYX-13, a NMDA receptor glycine-site functional partial agonist, induces antidepressant-like effects without ketamine-like side effects. Neuropsychopharmacology (2012) 1.74

Glutamate abnormalities in obsessive compulsive disorder: neurobiology, pathophysiology, and treatment. Pharmacol Ther (2011) 1.71

Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression. Biol Psychiatry (2012) 1.47

Glutamatergic modulators: the future of treating mood disorders? Harv Rev Psychiatry (2010) 1.42

Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? Neuropsychopharmacology (2014) 1.33

Review of pharmacological treatment in mood disorders and future directions for drug development. Neuropsychopharmacology (2011) 1.28

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses. Proc Natl Acad Sci U S A (2014) 1.26

Single treatments that have lasting effects: some thoughts on the antidepressant effects of ketamine and botulinum toxin and the anxiolytic effect of psilocybin. J Psychiatry Neurosci (2013) 1.25

Novel glutamatergic agents for major depressive disorder and bipolar disorder. Pharmacol Biochem Behav (2011) 1.24

Glutamate modulators as potential therapeutic drugs in schizophrenia and affective disorders. Eur Arch Psychiatry Clin Neurosci (2013) 1.24

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol (2014) 1.21

Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets. NeuroRx (2006) 1.19

Targeting the glutamatergic system to treat major depressive disorder: rationale and progress to date. Drugs (2012) 1.17

Pathophysiology of depression and innovative treatments: remodeling glutamatergic synaptic connections. Dialogues Clin Neurosci (2014) 1.15

Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias. Clin Interv Aging (2009) 1.14

The role of the tripartite glutamatergic synapse in the pathophysiology and therapeutics of mood disorders. Neuroscientist (2009) 1.13

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder. Int J Neuropsychopharmacol (2012) 1.11

Dual- and triple-acting agents for treating core and co-morbid symptoms of major depression: novel concepts, new drugs. Neurotherapeutics (2009) 1.10

Targeting glutamatergic signaling for the development of novel therapeutics for mood disorders. Curr Pharm Des (2009) 1.08

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists. Expert Opin Investig Drugs (2013) 1.07

Open-label memantine in fragile X syndrome. J Autism Dev Disord (2009) 1.04

Pharmacodynamics of memantine: an update. Curr Neuropharmacol (2008) 1.03

Novel glutamatergic drugs for the treatment of mood disorders. Neuropsychiatr Dis Treat (2013) 1.02

Evidence that Subanesthetic Doses of Ketamine Cause Sustained Disruptions of NMDA and AMPA-Mediated Frontoparietal Connectivity in Humans. J Neurosci (2015) 1.00

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study. Int J Geriatr Psychiatry (2011) 0.99

Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. CNS Spectr (2013) 0.99

Glutamate and its receptors in the pathophysiology and treatment of major depressive disorder. J Neural Transm (Vienna) (2013) 0.98

Ketamine and other N-methyl-D-aspartate receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis (2015) 0.98

Neuroinflammation, neurodegeneration, and depression. Neurotox Res (2012) 0.95

Rapid antidepressant effects: moving right along. Mol Psychiatry (2013) 0.93

BDNF - a key transducer of antidepressant effects. Neuropharmacology (2015) 0.93

How does ketamine elicit a rapid antidepressant response? Curr Opin Pharmacol (2014) 0.92

Common mechanisms of pain and depression: are antidepressants also analgesics? Front Behav Neurosci (2014) 0.92

A complex interaction between glycine/NMDA receptors and serotonergic/noradrenergic antidepressants in the forced swim test in mice. J Neural Transm (Vienna) (2011) 0.91

Ketamine elicits sustained antidepressant-like activity via a serotonin-dependent mechanism. Psychopharmacology (Berl) (2013) 0.91

Advances in the treatment of anxiety: targeting glutamate. NeuroRx (2006) 0.90

Bipolar disorder: candidate drug targets. Mt Sinai J Med (2008) 0.90

Emerging treatment mechanisms for depression: focus on glutamate and synaptic plasticity. Drug Discov Today (2016) 0.90

Involvement of normalized NMDA receptor and mTOR-related signaling in rapid antidepressant effects of Yueju and ketamine on chronically stressed mice. Sci Rep (2015) 0.86

Current status of ketamine and related compounds for depression. J Clin Psychiatry (2013) 0.86

Treatment of alcohol dependence in patients with co-morbid major depressive disorder--predictors for the outcomes with memantine and escitalopram medication. Subst Abuse Treat Prev Policy (2008) 0.85

Genetic ablation of the GluK4 kainate receptor subunit causes anxiolytic and antidepressant-like behavior in mice. Behav Brain Res (2011) 0.84

Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era. Expert Opin Pharmacother (2010) 0.84

Add-on memantine to valproate treatment increased HDL-C in bipolar II disorder. J Psychiatr Res (2013) 0.83

Antidepressant augmentation using the N-methyl-D-aspartate antagonist memantine: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry (2013) 0.83

Antidepressant action of ketamine via mTOR is mediated by inhibition of nitrergic Rheb degradation. Mol Psychiatry (2016) 0.83

AMPA Receptor-mTOR Activation is Required for the Antidepressant-Like Effects of Sarcosine during the Forced Swim Test in Rats: Insertion of AMPA Receptor may Play a Role. Front Behav Neurosci (2015) 0.82

Emerging targets for antidepressant therapies. Curr Opin Chem Biol (2009) 0.82

A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol (2015) 0.82

New targets for rapid antidepressant action. Prog Neurobiol (2015) 0.81

The role of GluN2A and GluN2B subunits on the effects of NMDA receptor antagonists in modeling schizophrenia and treating refractory depression. Neuropsychopharmacology (2014) 0.81

Potential of Glutamate-Based Drug Discovery for Next Generation Antidepressants. Pharmaceuticals (Basel) (2015) 0.80

Novel targets for antidepressant therapies. Curr Psychiatry Rep (2008) 0.80

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder. Mol Psychiatry (2015) 0.79

Memantine add on to citalopram in elderly patients with depression: A double-blind placebo-controlled study. J Res Med Sci (2014) 0.79

Antidepressant Actions of Ketamine Mediated by the Mechanistic Target of Rapamycin, Nitric Oxide, and Rheb. Neurotherapeutics (2017) 0.79

A neurocognitive model for understanding treatment action in depression. Philos Trans R Soc Lond B Biol Sci (2015) 0.78

Antidepressant, anxiolytic and procognitive effects of rivastigmine and donepezil in the chronic mild stress model in rats. Psychopharmacology (Berl) (2016) 0.78

Therapeutic Modulation of Glutamate Receptors in Major Depressive Disorder. Curr Neuropharmacol (2017) 0.78

GSK-3: a key regulatory target for ketamine's rapid antidepressant effects mediated by enhanced AMPA to NMDA throughput. Bipolar Disord (2016) 0.77

Novel Glutamatergic Treatments for Severe Mood Disorders. Curr Behav Neurosci Rep (2015) 0.77

Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics (2016) 0.77

Inflammation's Association with Metabolic Profiles before and after a Twelve-Week Clinical Trial in Drug-Naïve Patients with Bipolar II Disorder. PLoS One (2013) 0.77

Fluoxetine treatment induces EAAT2 expression in rat brain. J Neural Transm (Vienna) (2010) 0.77

Using an experimental medicine model to understand the antidepressant potential of the N-Methyl-D-aspartic acid (NMDA) receptor antagonist memantine. J Psychopharmacol (2012) 0.77

Hedonic sensitivity to low-dose ketamine is modulated by gonadal hormones in a sex-dependent manner. Sci Rep (2016) 0.77

Duality of Antidepressants and Neuroprotectants. Neurotox Res (2015) 0.77

Treatment-Resistant Major Depression: Rationale for NMDA Receptors as Targets and Nitrous Oxide as Therapy. Front Psychiatry (2015) 0.77

Instant and Lasting Down-Regulation of NR1 Expression in the Hippocampus is Associated Temporally with Antidepressant Activity After Acute Yueju. Cell Mol Neurobiol (2016) 0.76

Early intervention in bipolar disorder, part II: therapeutics. Early Interv Psychiatry (2008) 0.76

Ketamine and MAG Lipase Inhibitor-Dependent Reversal of Evolving Depressive-Like Behavior During Forced Abstinence From Alcohol Drinking. Neuropsychopharmacology (2016) 0.76

Advances in the Management of Treatment-Resistant Depression. Focus (Am Psychiatr Publ) (2010) 0.75

Failure of memantine to "reverse" quinpirole-induced hypomotility. World J Psychiatry (2016) 0.75

RAndomised controlled trial to imProve depressIon and the quality of life of people with Dementia using cognitive bias modification: RAPID study protocol. BMJ Open (2014) 0.75

Chronic stress prior to pregnancy potentiated long-lasting postpartum depressive-like behavior, regulated by Akt-mTOR signaling in the hippocampus. Sci Rep (2016) 0.75

A Clickable Analogue of Ketamine Retains NMDA Receptor Activity, Psychoactivity, and Accumulates in Neurons. Sci Rep (2016) 0.75

Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice. J Neural Transm (Vienna) (2016) 0.75

Synergistic antidepressant-like effect of the joint administration of caffeine and NMDA receptor ligands in the forced swim test in mice. J Neural Transm (Vienna) (2015) 0.75

Towards the Molecular Foundations of Glutamatergic-targeted Antidepressants. Curr Neuropharmacol (2017) 0.75

Reply to: Antidepressant Actions of Ketamine Versus Hydroxynorketamine. Biol Psychiatry (2016) 0.75

Current Trends in Identifying Rapidly Acting Treatments for Depression. Curr Behav Neurosci Rep (2016) 0.75

Experimental medication treatment approaches for depression. Transl Psychiatry (2017) 0.75

Case series: Antidepressant effects of low-affinity and low-trapping NMDA receptor antagonists did not predict response to ketamine in seven subjects. J Psychiatr Res (2016) 0.75

ON or OFF?: Modulating the N-Methyl-D-Aspartate Receptor in Major Depression. Front Mol Neurosci (2017) 0.75

Comparison of the Psychopharmacological Effects of Tiletamine and Ketamine in Rodents. Neurotox Res (2017) 0.75

ZL006, a small molecule inhibitor of PSD-95/nNOS interaction, does not induce antidepressant-like effects in two genetically predisposed rat models of depression and control animals. PLoS One (2017) 0.75

Prefrontal Connectivity and Glutamate Transmission: Relevance to Depression Pathophysiology and Ketamine Treatment. Biol Psychiatry Cogn Neurosci Neuroimaging (2017) 0.75

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry (2006) 11.84

Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors. Biol Psychiatry (2007) 6.59

Defining clinical phenotypes of juvenile mania. Am J Psychiatry (2003) 5.49

Discovering endophenotypes for major depression. Neuropsychopharmacology (2004) 4.90

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry (2010) 4.85

Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry (2013) 4.84

Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry (2005) 4.81

Targeting the glutamatergic system to develop novel, improved therapeutics for mood disorders. Nat Rev Drug Discov (2008) 4.46

Safety and efficacy of repeated-dose intravenous ketamine for treatment-resistant depression. Biol Psychiatry (2010) 4.00

Psychobiology and molecular genetics of resilience. Nat Rev Neurosci (2009) 3.71

Abnormal attention modulation of fear circuit function in pediatric generalized anxiety disorder. Arch Gen Psychiatry (2007) 3.10

The psychobiology of depression and resilience to stress: implications for prevention and treatment. Annu Rev Clin Psychol (2005) 3.09

Childhood trauma associated with smaller hippocampal volume in women with major depression. Am J Psychiatry (2002) 3.05

Publication bias and the efficacy of antidepressants. Am J Psychiatry (2009) 3.05

Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression. Biol Psychiatry (2009) 3.04

Adolescent immaturity in attention-related brain engagement to emotional facial expressions. Neuroimage (2003) 2.98

Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry (2010) 2.98

Ventrolateral prefrontal cortex activation and attentional bias in response to angry faces in adolescents with generalized anxiety disorder. Am J Psychiatry (2006) 2.90

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial. Biol Psychiatry (2012) 2.74

Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression. Biol Psychiatry (2012) 2.69

Reduced volume of orbitofrontal cortex in major depression. Biol Psychiatry (2002) 2.53

MRI and PET study of deficits in hippocampal structure and function in women with childhood sexual abuse and posttraumatic stress disorder. Am J Psychiatry (2003) 2.51

A functional magnetic resonance imaging study of bipolar disorder: state- and trait-related dysfunction in ventral prefrontal cortices. Arch Gen Psychiatry (2003) 2.36

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial. Int J Neuropsychopharmacol (2009) 2.33

The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J Neurosci (2003) 2.28

Impact of publicity concerning pediatric suicidality data on physician practice patterns in the United States. Arch Gen Psychiatry (2007) 2.25

VNS therapy in treatment-resistant depression: clinical evidence and putative neurobiological mechanisms. Neuropsychopharmacology (2006) 2.24

Ketamine for depression: where do we go from here? Biol Psychiatry (2012) 2.21

Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology (2012) 2.17

Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J Neurosci (2004) 2.17

Long-term treatment with paroxetine increases verbal declarative memory and hippocampal volume in posttraumatic stress disorder. Biol Psychiatry (2003) 2.16

Amygdala and hippocampal volumes in adolescents and adults with bipolar disorder. Arch Gen Psychiatry (2003) 2.15

Neurobiology of resilience. Nat Neurosci (2012) 2.13

Toward constructing an endophenotype strategy for bipolar disorders. Biol Psychiatry (2006) 2.09

Differential effects of 5-HTTLPR genotypes on the behavioral and neural responses to tryptophan depletion in patients with major depression and controls. Arch Gen Psychiatry (2006) 2.09

Attention bias to threat in maltreated children: implications for vulnerability to stress-related psychopathology. Am J Psychiatry (2005) 2.08

Increased anterior cingulate cortical activity in response to fearful faces: a neurophysiological biomarker that predicts rapid antidepressant response to ketamine. Biol Psychiatry (2008) 2.05

Life stress, genes, and depression: multiple pathways lead to increased risk and new opportunities for intervention. Sci STKE (2004) 2.04

Positron emission tomographic imaging of neural correlates of a fear acquisition and extinction paradigm in women with childhood sexual-abuse-related post-traumatic stress disorder. Psychol Med (2005) 1.99

Response to emotional expressions in generalized social phobia and generalized anxiety disorder: evidence for separate disorders. Am J Psychiatry (2008) 1.99

Trauma exposure, posttraumatic stress disorder and depression in an African-American primary care population. J Natl Med Assoc (2006) 1.95

The neurobiology of the switch process in bipolar disorder: a review. J Clin Psychiatry (2010) 1.94

Neural and behavioral responses to tryptophan depletion in unmedicated patients with remitted major depressive disorder and controls. Arch Gen Psychiatry (2004) 1.92

Glycogen synthase kinase-3: a putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (2005) 1.90

Trauma, resilience, and recovery in a high-risk African-American population. Am J Psychiatry (2008) 1.89

Neural correlates of the classic color and emotional stroop in women with abuse-related posttraumatic stress disorder. Biol Psychiatry (2004) 1.85

AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int J Neuropsychopharmacol (2004) 1.79

Evidence for selective microRNAs and their effectors as common long-term targets for the actions of mood stabilizers. Neuropsychopharmacology (2008) 1.79

A randomized trial of a low-trapping nonselective N-methyl-D-aspartate channel blocker in major depression. Biol Psychiatry (2012) 1.76

Efficacy of a protein kinase C inhibitor (tamoxifen) in the treatment of acute mania: a pilot study. Bipolar Disord (2007) 1.74

Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method. J Clin Psychiatry (2003) 1.72

An open-label trial of riluzole in patients with treatment-resistant major depression. Am J Psychiatry (2004) 1.71

Enhancing neuronal plasticity and cellular resilience to develop novel, improved therapeutics for difficult-to-treat depression. Biol Psychiatry (2003) 1.71

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist. Biol Psychiatry (2008) 1.71

Hippocampal volume, memory, and cortisol status in major depressive disorder: effects of treatment. Biol Psychiatry (2004) 1.70

Frontostriatal abnormalities in adolescents with bipolar disorder: preliminary observations from functional MRI. Am J Psychiatry (2003) 1.70

Increased amygdala activity during successful memory encoding in adolescent major depressive disorder: An FMRI study. Biol Psychiatry (2006) 1.68

Rapid and non-rapid cycling bipolar disorder: a meta-analysis of clinical studies. J Clin Psychiatry (2003) 1.68

Regional brain metabolic correlates of alpha-methylparatyrosine-induced depressive symptoms: implications for the neural circuitry of depression. JAMA (2003) 1.67

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression. Biol Psychiatry (2005) 1.65

Cellular plasticity cascades: targets for the development of novel therapeutics for bipolar disorder. Biol Psychiatry (2006) 1.65

An overview of posttraumatic stress disorder in African Americans. J Clin Psychol (2006) 1.65

The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology (2006) 1.64

Developing an agenda for translational studies of resilience and vulnerability following trauma exposure. Ann N Y Acad Sci (2006) 1.62

Enduring mental health morbidity and social function impairment in world trade center rescue, recovery, and cleanup workers: the psychological dimension of an environmental health disaster. Environ Health Perspect (2008) 1.62

The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis. Bipolar Disord (2009) 1.62

Deficits in social cognition and response flexibility in pediatric bipolar disorder. Am J Psychiatry (2005) 1.62

Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci (2004) 1.61

Neural correlates of declarative memory for emotionally valenced words in women with posttraumatic stress disorder related to early childhood sexual abuse. Biol Psychiatry (2003) 1.61

Frontotemporal alterations in pediatric bipolar disorder: results of a voxel-based morphometry study. Arch Gen Psychiatry (2005) 1.57

Rapid onset of antidepressant action: a new paradigm in the research and treatment of major depressive disorder. J Clin Psychiatry (2008) 1.57

An integrated approach to evaluate faculty members' research performance. Acad Med (2009) 1.56

Mood disorders and medical illness: a major public health problem. Biol Psychiatry (2003) 1.56

A case of sustained remission following an acute course of ketamine in treatment-resistant depression. J Clin Psychiatry (2011) 1.55

Effects of tryptophan depletion on serum levels of brain-derived neurotrophic factor in unmedicated patients with remitted depression and healthy subjects. Am J Psychiatry (2005) 1.55

The Wnt signaling pathway in bipolar disorder. Neuroscientist (2002) 1.53

Brain-derived neurotrophic factor and initial antidepressant response to an N-methyl-D-aspartate antagonist. J Clin Psychiatry (2009) 1.51